Table 1 Overview of patient characteristics.
From: Ikaros expression is associated with an increased risk of chronic graft-versus-host disease
N | 66 |
Age, years (range) | 52 (16–80) |
Male sex, n (%) | 36 (55) |
Diagnostic, n (%) | |
AML | 27 (41) |
ALL | 11 (17) |
MDS/MPN | 13 (20) |
Lymphoma | 8 (12) |
Aplastic anemia | 7 (10) |
Graft source, n (%) | |
Bone marrow | 15 (23) |
Mobilized peripheral blood | 51 (77) |
Donor, n (%) | |
Haploidentical | 32 (48) |
Related | 19 (29) |
Unrelated | 15 (23) |
Reduced conditioning intensity, n (%) | 54 (82) |
Use of total body irradiation, n (%) | 38 (58) |
Use of anti-thymocyte globulin, n (%) | 17 (26) |
Graft versus host disease prophylaxis, n (%) | |
CsA + MMF + Post-Cy | 38 (58) |
CsA + MMF | 22 (33) |
CsA + MTX | 6 (9) |
Median follow up, months (range) | 18 (10–43) |
